Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | -6.04% |
|
0.00% | -41.42% |
06-17 | Rallybio Corporation Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Rlybocytopenia | CI |
05-15 | JPMorgan Downgrades Rallybio to Neutral From Overweight | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.42% | 61.76M | |
+23.13% | 52.73B | |
+37.49% | 39B | |
-8.73% | 38.52B | |
+28.09% | 30.38B | |
-12.26% | 26.39B | |
+10.57% | 26.08B | |
+45.05% | 14.15B | |
+32.23% | 12.6B | |
-6.56% | 11.51B |
- Stock Market
- Equities
- RLYB Stock
- News Rallybio Corporation
- JMP Securities Adjusts Price Target on Rallybio to $16 From $26, Maintains Market Outperform Rating